Sign Up
Stories
Biotech Deal: Roivant and Roche
Share
Biotech Downturn and Funding Challenges
Biotech Industry Updates and Conferences
Biotech Innovations and Financing
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Afya Limited Expands Medical Seats in Br...
Overview
API
Roivant Sciences is in talks with Roche to sell an experimental drug, RVT-3101, for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, in a potential deal valued over $7 billion.
Ask a question
How might this deal impact the pharmaceutical industry and the treatment of inflammatory bowel diseases?
How might this deal influence the competitive landscape of the biotech market?
What are the potential implications for Vivek Ramaswamy's presidential candidacy given this significant biotech deal?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
May 2023
Jun 2023
Jul 2023
Coverage